If you are a generic company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners. Read more about Newport Premium (for Generics).

If you are an API manufacturer, we can help you target products for development, uncover buyers for your active ingredients, monitor your competition, and find partners. Read more about Newport Premium (for Generics).

If you are an innovator, we can help you monitor your competition, find licensing partners, and locate sources of API. Read more about Newport Premium (for Innovators).

If you are specialty company, we can help you target products for development, locate qualified sources of API, monitor your competition, and find partners and licensing opportunities.  Read more about Newport Premium (for Innovators).

If you are a PBM, health insurer, or retail pharmacy, we can help you manage your costs by enabling you to identify likely suppliers and their relative negotiating strengths, intensity of competition, and timing of generic entry. Read more about Newport Premium (for Generics).

If you are a financial company, we can help you monitor generic competition for key products and companies. Read more about Newport Premium (for Generics).

Our solutions for Generics, API Manufacturers, PBMs, Pharmacies, and Analysts

• Newport Premium (for Generics): The critical product targeting, global business development and API sourcing system from Thomson Reuters, the industry authority on the global generics market.
• Newport Phase III Drugs ModulePDF Intelligence on products still in phase III clinical trials or going through registrations.
• Newport Generic Deals ModulePDF 2ND PAGE:Thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.
• Newport US Market Share ModulePDF 2ND PAGE:10 years of product market share history that can be analyzed by dose form, strength, marketer, and brand vs. generic. This module integrates seamlessly with Newport Global or Newport Premium base systems, considerably enhancing the visibility of industry dynamics and insight into the U.S. pharmaceutical market. Request more information on the Newport US Market Share Module
• Newport Biologics ModulePDF:In March 2011, we will launch the Newport Biologics Module which contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is U.S. BLA (Biologics License Application) data for drugs approved through this regulatory route. Request more information on the Newport Biologics Module

Our solutions for Innovators

• Newport Premium (for Innovators):The most advanced competitive intelligence, business development and global active pharmaceutical ingredient (API) sourcing system from Thomson Reuters, the industry authority on the global generics market.
• Newport Generic Deals ModulePDF 2ND PAGE:Thousands of merger, acquisition, development, supply, manufacturing, joint venture, patent settlement and authorized generic deals involving generic companies worldwide since 1999.
• Newport US Market Share ModulePDF 2ND PAGE:10 years of product market share history that can be analyzed by dose form, strength, marketer, and brand vs. generic. This module integrates seamlessly with Newport Global or Newport Premium base systems, considerably enhancing the visibility of industry dynamics and insight into the U.S. pharmaceutical market. Request more information on the Newport US Market Share Module
• Newport Biologics ModulePDF:In March 2011, we will launch the Newport Biologics Module which contains unique manufacturing process data covering biologic drugs, including recombinant proteins, antibodies, factors, and vaccines. Companies considering pursuing biosimilar opportunities can analyze multiple potential bio-manufacturing processes for each drug, genetic sequences, process steps, starting materials, and equipment required, as well as review related patents and literature references. Also included is U.S. BLA (Biologics License Application) data for drugs approved through this regulatory route. Request more information on the Newport Biologics Module

FREE WEBINAR - Thursday, August 12

API & Finished Dose Medicines: The Importance of Product Targeting to Gain Market Share

9am San Francisco | 11am Chicago | 12pm New York

The pharmaceutical market is rapidly changing and getting more competitive as increasingly more companies are competing for a slice of the market.

Newport Product Specialist, David Harding, will provide an in-depth analysis on the API & Finished Dose market, analyzing the competitive landscape, partnerships, growth opportunities, as well as the emergence of biosimilars. He will share some valuable strategies for targeting products for development and will explain how successful companies are targeting products earlier in the pipeline. Don't miss out, register today!

2nd Annual Business of Biosimilars

Seizing Commercial Opportunities in the United States and Abroad

September 20-22, 2010 | Hyatt Regency Boston, MA

• Evaluate scientific implications of biosimilars
• Build strategic alliances with emerging markets
• Adopt effective IP protection and patent litigation strategies
• Obtain techniques for product launch and marketing
• Navigate global regulations and legislation

Visit biosimilarsevent.com for more information.

MORE FROM NEWPORT

• Download glossary of industry terms PDF
• Need technical assistance? Contact our support team

FREE EXPERT SLIDES

Enhance your presentations and reports with clearly presented information on trends in the pharmaceutical industry. Find out more